Canine leukoreduction review finds promise, but limited proof

A new critically appraised topic in Veterinary Sciences argues that the clinical case for routine prestorage leukoreduction of canine blood products is still unsettled. The review asks whether leukoreduced canine blood products outperform standard products on four fronts: product quality, inflammatory response, transfusion reactions, and patient-centered outcomes. Its bottom line is cautious: leukoreduction appears technically effective and may improve some laboratory measures, but the canine evidence base remains too thin to prove consistent clinical benefit. (onlinelibrary.wiley.com)

That conclusion fits the broader history of the issue. In human medicine, leukoreduction became widely adopted because it can reduce febrile non-hemolytic transfusion reactions and limit other leukocyte-related effects. In veterinary medicine, though, uptake has been much more limited, and the evidence base is much smaller. The AVHTM Transfusion Reaction Small Animal Consensus Statement, published in 2021, concluded there was insufficient evidence to recommend for or against leukoreduction in dogs and cats, while still suggesting it should be considered because of human data and the biologic rationale for reducing cytokine accumulation during storage. (onlinelibrary.wiley.com)

The underlying science is part of what keeps the question alive. Earlier canine work showed prestorage filtration can effectively remove leukocytes while preserving red cell viability, and later studies found leukoreduction can alter storage lesions in whole blood and packed red cells. One 2021 study reported that leukoreduction changed some coagulation-related measures in canine plasma, including prolonged aPTT and reduced factor XI activity, although the authors said those changes were unlikely to compromise therapeutic quality apart from that factor-specific effect. More recent work has continued to explore how leukoreduction interacts with oxidative stress, hemolysis, and storage-related product changes. (pubmed.ncbi.nlm.nih.gov)

Where the evidence gets weaker is at the bedside. A randomized clinical trial in critically ill dogs found prestorage leukoreduction did not clearly reduce post-transfusion inflammatory markers compared with non-leukoreduced red cells, and the authors called for larger studies. A retrospective study of 339 dogs receiving 413 packed red cell units likewise found no significant association between leukocyte depletion and febrile non-hemolytic transfusion reactions, other transfusion reactions, post-transfusion PCV change, or survival to discharge. In that cohort, total transfusion reactions occurred in 18.4% of transfused units, with no significant difference between leukoreduced and non-leukoreduced products. (pubmed.ncbi.nlm.nih.gov)

Industry or outside expert reaction appears limited so far, but the consensus view in the literature is fairly consistent: leukoreduction is promising, especially from a product-quality standpoint, yet still unproven as a routine standard for canine transfusion practice. The AVHTM panel summarized that tension directly, noting insufficient veterinary evidence for a recommendation while still acknowledging reasons to consider prestorage leukoreduction. That makes this less a story of reversal than of consolidation, with the new review pulling scattered canine studies into a more explicit evidence-based framework. (onlinelibrary.wiley.com)

Why it matters: For veterinarians, emergency clinicians, and blood bank teams, the practical question is whether leukoreduction delivers enough clinical value to justify added cost, processing time, and possible product loss. Existing studies suggest it may improve some laboratory indicators of blood product quality, but they haven't yet shown a reliable reduction in transfusion reactions or better patient outcomes. For now, that leaves decisions about leukoreduction tied to local protocols, case mix, and resource constraints rather than a clear profession-wide standard. (pmc.ncbi.nlm.nih.gov)

There's also a nuance here for referral hospitals and transfusion services: even if universal leukoreduction isn't evidence-backed today, targeted use could still emerge as a rational strategy. The literature points to unanswered questions around older stored units, critically ill recipients, inflammatory phenotypes, and whether specific products or patient subgroups might benefit more than the average canine transfusion recipient. That's likely where the next meaningful studies will focus. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next step is likely larger prospective, ideally multicenter canine trials that use standardized transfusion reaction definitions and look beyond surrogate markers to outcomes clinicians and pet parents actually care about, including reaction rates, recovery, length of hospitalization, and survival. (onlinelibrary.wiley.com)